Oneness (TWSE: 4743) has been included in the S&P Global Sustainability Yearbook for the third consecutive year, making it the only Taiwanese company to rank among the top 10 in the global Pharmaceuticals Industry category.
S&P Global is one of the world’s most reputable ESG rating agencies, publishing the Sustainability Yearbook based on its Corporate Sustainability Assessment (CSA). In 2025, the Yearbook selected 780 companies with the best ESG performance from 7,690 companies across 62 industries worldwide. Oneness was the first Taiwanese company to be listed under the Pharmaceuticals Industry category in 2023 and has successfully retained its position for the third year in a row.
Oneness has demonstrated outstanding performance across all three ESG dimensions in S&P Global CSA. In particular, the Company ranked first globally in the Pharmaceuticals Industry for Governance and Economic Dimension, showcasing its excellence in operational transparency, risk management, corporate ethics, and regulatory compliance. Among the 24 evaluation criteria, Oneness ranked in the top 10% globally in 22 categories, with 16 categories placing in the top 5% and 6 receiving full scores, including transparency, innovation management, product stewardship, and customer relations, reinforcing its global competitiveness.
Chairman Dr. Hsien-Shou Kuo stated, "Since its establishment 16 years ago, Oneness has built strong international competitiveness in both 'product development' and 'corporate governance.' Our current focus is on global market expansion, systematically working towards our third major goal—'business development.' We are actively expanding into various markets, including China, the United States, Europe, the Middle East, and Latin America. Our first commercialized product is an innovative prescription wound care treatment with a novel mechanism of action. Given the specialized nature of this treatment, its promotion requires extensive engagement with medical professionals, making market adoption more challenging than other drug categories. However, with our team’s dedication, we anticipate significant breakthroughs this year."
He further emphasized that Oneness’ commitment to ESG and sustainable development is not only a foundation for long-term business growth but also a reflection of its corporate social responsibility. Being listed in the S&P Global Sustainability Yearbook for three consecutive years is a strong recognition of Oneness’ efforts in environmental protection, social impact, and corporate governance. Moving forward, the company will continue to drive forward-thinking innovation, responsible operations, and transparent governance, achieving a win-win for corporate growth and global sustainability.
